HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Rides Standalone Consumer Health Track

Executive Summary

J&J takes same approach GSK, Pfizer, Merck & Co, Merck and Novartis have with their consumer health businesses, Bausch Health is starting and Sanofi says it will.

You may also be interested in...



AESGP Annual Meeting, Day 2 (Part 1): The Future For Europe’s Self-Care Industry Is Bright And Digital

Day 2 of the AESGP’s 58th Annual Meeting in Madrid, Spain begins with optimism about the future of the European self-care industry. Google and IQVIA Consumer Health analyze COVID-19 trends to help industry prepare for the post-pandemic new normal, while Convert Group and Swedish e-pharmacy Meds.se emphasize the opportunity presented by e-commerce for consumer health.

Self-Care Only Option For Some People, But Consumer Health Products Don’t Reach All

Heiko Schipper, Global Self-Care Federation chairman and Bayer’s consumer health business head, says for some consumers, “it’s this or nothing.” Federation study found between $100bn and $200bn is saved annually worldwide from consumers spending on self-care rather than medical care.

‘Increasingly Challenging’ Environment Shifted J&J's Plans Toward Consumer Business Separation

Pharma R&D VP Mathai Mammen acknowledges “pros and cons to remaining” as one company but dismissed “any meaningful downside” for the pharma business, which along with the device business will continue operating as J&J.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151944

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel